Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance ...
Humacyte announces publication of results on ATEV
Humacyte (HUMA) announced the publication of clinical results evaluating the efficacy and safety of the acellular tissue engineered vessel, ...
Morningstar3d
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks ...
Yahoo Finance3d
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
The publication “Bioengineered Human Arteries for the Repair of Vascular Injuries” describes two clinical studies in which the ATEV demonstrated benefits in terms of patency (blood flow), limb ...
Mena FN3d
Humacyte Clinical Results Highlighting Benefit Of The ATEV™ In The Repair Of Civilian And Military Arterial Injuries Published In JAMA Surgery
(MENAFN- GlobeNewsWire - Nasdaq) – In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current ...
Humacyte sees success in dual emergency-engineered tissue trials
The two studies of the company’s engineered vascular tissue saw success with casualties in Ukraine and the US.
Investing3d
Bioengineered arteries show promise in trauma care
DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology firm, announced clinical results suggesting its acellular tissue engineered vessel (ATEV) could be more effective than synthetic grafts ...
TMCnet3d
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)
On October 17, 2024, during market hours, the FDA released a Form 483 concerning Humacyte's Durham, North Carolina facility, which revealed a number of violations, including "no microbial quality ...
TMCnet4d
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA) and reminds investors of the January ...